JP2021506922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506922A5 JP2021506922A5 JP2020534482A JP2020534482A JP2021506922A5 JP 2021506922 A5 JP2021506922 A5 JP 2021506922A5 JP 2020534482 A JP2020534482 A JP 2020534482A JP 2020534482 A JP2020534482 A JP 2020534482A JP 2021506922 A5 JP2021506922 A5 JP 2021506922A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711408330 | 2017-12-22 | ||
| CN201711408330.4 | 2017-12-22 | ||
| PCT/CN2018/122534 WO2019120269A1 (zh) | 2017-12-22 | 2018-12-21 | Lag-3抗体药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506922A JP2021506922A (ja) | 2021-02-22 |
| JP2021506922A5 true JP2021506922A5 (https=) | 2021-12-23 |
Family
ID=66993121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534482A Pending JP2021506922A (ja) | 2017-12-22 | 2018-12-21 | Ｌａｇ−３抗体医薬組成物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220031842A1 (https=) |
| EP (1) | EP3714901A4 (https=) |
| JP (1) | JP2021506922A (https=) |
| KR (1) | KR20200104314A (https=) |
| CN (1) | CN111356476B (https=) |
| AU (1) | AU2018391217A1 (https=) |
| BR (1) | BR112020011664A2 (https=) |
| CA (1) | CA3085656A1 (https=) |
| RU (1) | RU2771384C2 (https=) |
| TW (1) | TWI869334B (https=) |
| WO (1) | WO2019120269A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN110787292B (zh) * | 2020-01-06 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 一种细胞程序性死亡受体1抗体制剂及其用途 |
| CN114504642B (zh) * | 2020-11-17 | 2026-03-27 | 江苏奥赛康生物医药有限公司 | 一种含抗cldn18.2抗体的液体药物组合物 |
| CN114617961B (zh) * | 2020-12-10 | 2022-12-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3单克隆抗体的注射制剂 |
| EP4403573A4 (en) * | 2021-09-15 | 2024-12-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING BISPECIFIC ANTI-PVRIG/TIGIT ANTIBODY |
| JP2024536881A (ja) * | 2021-09-29 | 2024-10-08 | 中山康方生物医▲藥▼有限公司 | 抗ｌａｇ３抗体、医薬組成物、及び使用 |
| CN114874324B (zh) * | 2022-05-13 | 2023-02-03 | 苏州旭光科星抗体生物科技有限公司 | 一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用 |
| CN121889167A (zh) * | 2023-09-13 | 2026-04-17 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| CN117159703B (zh) * | 2023-11-02 | 2024-04-02 | 正大天晴(广州)医药有限公司 | 含抗lag-3抗体的药物组合物及其用途 |
| CN120754244B (zh) * | 2025-09-10 | 2025-12-12 | 江苏豪森药业集团有限公司 | 一种含抗cd19抗体的药物组合物及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2189657C (fr) * | 1994-05-06 | 2002-03-12 | Florence Faure | Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PL1897548T5 (pl) | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| US10344088B2 (en) | 2013-03-15 | 2019-07-09 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| AU2014347004B2 (en) * | 2013-11-05 | 2019-08-08 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
| CN106061488B (zh) * | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| WO2015198312A1 (en) * | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN114853891A (zh) * | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| CN117510633A (zh) * | 2015-09-02 | 2024-02-06 | 伊缪泰普有限公司 | 抗lag-3抗体 |
| RS61510B1 (sr) * | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anti pd-1 i anti-lag3 antitela za lečenje kancera |
| US11155617B2 (en) * | 2016-06-23 | 2021-10-26 | Jiangsu Hengrui Medicine Co., Ltd. | LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
-
2018
- 2018-12-21 CA CA3085656A patent/CA3085656A1/en active Pending
- 2018-12-21 RU RU2020118313A patent/RU2771384C2/ru active
- 2018-12-21 WO PCT/CN2018/122534 patent/WO2019120269A1/zh not_active Ceased
- 2018-12-21 US US16/954,176 patent/US20220031842A1/en not_active Abandoned
- 2018-12-21 KR KR1020207018644A patent/KR20200104314A/ko not_active Withdrawn
- 2018-12-21 CN CN201880059038.2A patent/CN111356476B/zh active Active
- 2018-12-21 JP JP2020534482A patent/JP2021506922A/ja active Pending
- 2018-12-21 AU AU2018391217A patent/AU2018391217A1/en not_active Abandoned
- 2018-12-21 EP EP18892762.8A patent/EP3714901A4/en not_active Withdrawn
- 2018-12-21 TW TW107146459A patent/TWI869334B/zh active
- 2018-12-21 BR BR112020011664-5A patent/BR112020011664A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506922A5 (https=) | ||
| RU2020118313A (ru) | Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение | |
| TWI880888B (zh) | 抗體－藥物結合物之製劑及其冷凍乾燥方法 | |
| JP2016534052A5 (https=) | ||
| US20100260766A1 (en) | Stable antibody formulations | |
| JP2022065061A (ja) | パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法 | |
| CN106999591A (zh) | 一种抗pd‑1抗体制剂及其在医药上的应用 | |
| JP4854912B2 (ja) | 癌に対する抗体 | |
| JP2021504372A5 (https=) | ||
| US20090306348A1 (en) | Antibody Formulation | |
| BR112020015479A2 (pt) | Anticorpos anticlaudina 18.2 e usos dos mesmos | |
| EP2061510B1 (en) | Treatment and/or prevention of barrett's esophagus using anti-ephb4 antibody-containing compositions | |
| JP6917681B2 (ja) | 腫瘍性疾患のための治療 | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| TW200815029A (en) | Anti-IGF-1R human monoclonal antibody formulation | |
| US20100158919A1 (en) | Pharmaceutical Composition | |
| KR20210101336A (ko) | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 | |
| CN110075295A (zh) | 具有cl2a接头的抗体-sn-38免疫缀合物 | |
| JP2022526694A (ja) | 腫瘍治療用の併用医薬組成物 | |
| CN109963581A (zh) | 一种il-15蛋白复合物药物组合物及其用途 | |
| CN110382008A (zh) | 一种含c-Met抗体药物偶联物的药物组合物及其用途 | |
| TW202130349A (zh) | Ｐｄ－１抗體聯合紫杉類化合物在製備治療三陰性乳腺癌的藥物中的用途 | |
| CN110859959A (zh) | 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途 | |
| JP2025535500A (ja) | 抗ネクチン－４抗体－薬物コンジュゲートを含む調製物及びその使用 | |
| KR20250134646A (ko) | 유방암 치료용 항-her2 항체-약물 접합체 |